Banque Pictet & Cie SA raised its stake in Humana Inc. (NYSE:HUM - Free Report) by 114.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,541 shares of the insurance provider's stock after acquiring an additional 20,031 shares during the quarter. Banque Pictet & Cie SA's holdings in Humana were worth $9,525,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in HUM. FNY Investment Advisers LLC raised its stake in Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider's stock valued at $6,916,000 after purchasing an additional 26,856 shares during the last quarter. Retirement Systems of Alabama raised its position in shares of Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock valued at $55,563,000 after buying an additional 192,801 shares during the last quarter. PDT Partners LLC lifted its stake in shares of Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider's stock valued at $1,286,000 after buying an additional 2,660 shares during the period. Secure Asset Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $244,000. Finally, Ontario Teachers Pension Plan Board grew its stake in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider's stock worth $371,705,000 after acquiring an additional 71,910 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.
Humana Stock Up 1.3 %
Humana stock traded up $3.41 during midday trading on Tuesday, hitting $257.24. 1,418,958 shares of the company were exchanged, compared to its average volume of 1,706,863. The company has a market cap of $30.97 billion, a PE ratio of 22.78, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company's fifty day moving average price is $270.62 and its 200-day moving average price is $292.21. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, research analysts predict that Humana Inc. will post 16.11 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have weighed in on HUM. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Morgan Stanley decreased their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday. Finally, Wells Fargo & Company dropped their price target on shares of Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $285.68.
Check Out Our Latest Research Report on Humana
Insider Buying and Selling at Humana
In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company's stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.32% of the stock is currently owned by corporate insiders.
Humana Company Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
